NCT06001151

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

Name: Clinical Trial NCT06001151
Creator: Qian Chu
Keywords: Carcinoma, Non-Small-Cell Lung, Cadonilimab, Phase 2, drug, clinical trial, China

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative：A Multi-center, Single-arm, Phase II Study

Qian Chu·Phase 2·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Carcinoma, Non-Small-Cell Lung
Drug/Device/Intervention: Cadonilimab
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Qian Chu
Funder: Tongji Hospital
Location: Wuhan, China

Timeline & enrollment

Phase: Phase 2
Start date: Aug 07, 2023
End date: Aug 31, 2027
Enrollment: 49 participants

Primary outcome

12-month progression-free-survival (PFS) rate

Summary

This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific antibody.

ICD-10 classifications

Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06001151
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06001151 through Pure Global AI's free database. This Phase 2 trial is sponsored by Qian Chu and is currently Recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 49 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.